Aridis Pharmaceuticals,Inc. (NASDAQ: ARDS) Files An 8-K Other Events

ME Staff 8-k
-
0
Aridis Pharmaceuticals,Inc. (NASDAQ: ARDS) Files An 8-K Other Events

Aridis Pharmaceuticals,Inc. (NASDAQ: ARDS) Files An 8-K Other Events
Item 8.01 Other Events.

On December4, 2018, Aridis Pharmaceuticals,Inc. issued a press release announcing that the Cystic Fibrosis Foundation (CF Foundation) has more than doubled its research agreement for the clinical development program of AR-501 from $2.9 million to up to $7.5 million. A copy of the press release is furnished as Exhibit99.1 to this Form8-K.

Item 9.01. Financial Statements and Exhibits

(d)Exhibits.

99.1

Press Release of Aridis Pharmaceuticals,Inc. dated December4, 2018


Aridis Pharmaceuticals, Inc. Exhibit
EX-99.1 2 a18-41125_1ex99d1.htm EX-99.1 Exhibit 99.1   Aridis Expands Research Agreement with the Cystic Fibrosis Foundation and is awarded FDA Expedited Program Designations   ·                  CF Foundation expands research agreement for AR-501 (for cystic fibrosis) to include additional award amount of up to $4.6 million ·                  FDA grants Fast-Track and QIDP Designations for AR-501,…
To view the full exhibit click here